Table of Contents
- 1 1. Gamida Cell Ltd (NASDAQ: GMDA)
- 2 2. Adaptimmune Therapeutics plc (NASDAQ: ADAP)
- 3 3. Inovio Pharmaceuticals, Inc. (NASDAQ: INO)
- 4 4. Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE)
- 5 5. Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)
- 6 6. Applied Genetic Technologies Corporation (NASDAQ: AGTC)
- 7 7. Brickell Biotech, Inc. (NASDAQ: BBI)
- 8 8. Amyris, Inc. (NASDAQ: AMRS)
- 9 9. Harvard Bioscience, Inc. (NASDAQ: HBIO)
- 10 10. Anixa Biosciences, Inc. (NASDAQ: ANIX)
- 11 11. AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC)
- 12 12. Aptose Biosciences Inc. (NASDAQ: APTO)
- 13 13. AgeX Therapeutics, Inc. (NYSE: AGE)
- 14 14. Edesa Biotech, Inc. (NASDAQ: EDSA)
- 15 15. Orgenesis Inc. (NASDAQ: ORGS)
The Biotech industry is a promising one, everyone (informed ones) knows that. And it’s not just promising because it’s a huge industry that draws in huge revenues; it’s promising because it has a track record of being highly profitable for both short-term traders and long-term investors.
According to GrandViewResearch, “the global biotechnology market size is expected to reach USD 727.1 billion by 2025, at a CAGR of 7.4% according to a new report by Grand View Research, Inc. The emergence of certain key themes in the market is expected to drive growth in this industry to a lucrative extent”.
Checkout: Blockchain Penny Stocks under $3
Biotech stocks are lucrative to an ‘extent’, because of the nature of the Biotech industry, biotech penny stocks are best traded for short-term gains. As such timing is important for successfully trading biotech stocks; getting in in time and getting out in the same fashion.
If you are interested in Biotech Penny Stocks under $5 and $10, here are cheap Biotech stocks to consider trading:
1. Gamida Cell Ltd (NASDAQ: GMDA)
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases.
The company’s lead product candidate is omidubicel, a nicotinamide expanded hematopoietic stem cells and differentiated immune cells, including T cells that is in Phase 3 studies in patients with high-risk hematologic malignancies, as well as in Phase 1/2 clinical trial in patients with severe aplastic anemia.
It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma.
The company was founded in 1998 and is headquartered in Jerusalem, Israel.
2. Adaptimmune Therapeutics plc (NASDAQ: ADAP)
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.
The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
3. Inovio Pharmaceuticals, Inc. (NASDAQ: INO)
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.
The firm’s drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies.
The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
4. Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE)
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases.
Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.
The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
5. Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.
The company’s oncology development programs include CYC065, a cyclin-dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia.
In addition, the company’s oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis.
Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
6. Applied Genetic Technologies Corporation (NASDAQ: AGTC)
Applied Genetic Technologies Corp. engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases.
It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology.
The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999, and is headquartered in Alachua, FL.
7. Brickell Biotech, Inc. (NASDAQ: BBI)
Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases.
Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma, and psoriasis.
The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.
8. Amyris, Inc. (NASDAQ: AMRS)
Amyris, Inc. engages in the provision of bioscience solutions. It offers its products to health and wellness, clean beauty, and flavor and fragrance markets.
The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.
9. Harvard Bioscience, Inc. (NASDAQ: HBIO)
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development.
It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force.
The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.
10. Anixa Biosciences, Inc. (NASDAQ: ANIX)
Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body’s immune system in the fight against cancer.
It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.
The company was founded on November 5, 1982 and is headquartered San Jose, CA.
11. AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC)
Anpac Bio-Medical Science Co. Ltd., is a biotechnology company. It engages in marketing and selling multi-cancer screening and detection test that uses patented cancer differentiation analysis, or CDA, technology and proprietary cancer-detection device or CDA device.
The company was founded by Chris Chang Yu and He Yu in 2010 and is headquartered in Lishui, China.
12. Aptose Biosciences Inc. (NASDAQ: APTO)
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies.
Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent.
The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
13. AgeX Therapeutics, Inc. (NYSE: AGE)
AgeX Therapeutics, Inc. operates as a biotechnology company. It focuses on the development and commercialization of novel therapeutics targeting human aging.
The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.
14. Edesa Biotech, Inc. (NASDAQ: EDSA)
Edesa Biotech, Inc. is a biopharmaceutical company. It focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs.
The company was founded in 2015 and is headquartered in Markham, Canada.
15. Orgenesis Inc. (NASDAQ: ORGS)
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry.
It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment through MaSTherCell, comprises of services from cell therapy development through cell therapy manufacturing for and companies that provide end-to-end solution.
The POC segment provides multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration.
The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.
Henry John is a Stock Portfolio Manager that focuses on companies developing cutting-edge technologies.
Keeping track of cutting-edge techs, companies and stocks is what I do almost everyday. And I love it. Whether it’s artificial intelligence, 5g, or autonomous vehicles; I’m all in.
I’m a self-made millionaire who made most of his money investing in technology companies while working in finance.
Yes! I owe it all to tech and finance.